A rational use of clozapine based on adverse drug reactions, pharmacokinetics, and clinical pharmacopsychology
J de Leon, CJ Ruan, G Schoretsanitis… - Psychotherapy and …, 2020 - karger.com
Abstract Using Richardson and Davidson's model and the sciences of pharmacokinetics and
clinical pharmacopsychology, this article reviewed the:(1) poor life expectancy associated …
clinical pharmacopsychology, this article reviewed the:(1) poor life expectancy associated …
Clinical pharmacokinetics of atypical antipsychotics: an update
MC Mauri, S Paletta, C Di Pace, A Reggiori… - Clinical …, 2018 - Springer
Therapeutic drug monitoring studies have generally concentrated on controlling compliance
and avoiding side effects by maintaining long-term exposure to minimally effective blood …
and avoiding side effects by maintaining long-term exposure to minimally effective blood …
[ספר][B] The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia
American Psychiatric Association - 2020 - psychiatryonline.org
The goal of this guideline is to improve the quality of care and treatment outcomes for
patients with schizophrenia, as defined by the Diagnostic and Statistical Manual of Mental …
patients with schizophrenia, as defined by the Diagnostic and Statistical Manual of Mental …
Association of CYP2C19 and CYP2D6 poor and intermediate metabolizer status with antidepressant and antipsychotic exposure: a systematic review and meta …
Importance Precise estimation of the drug metabolism capacity for individual patients is
crucial for adequate dose personalization. Objective To quantify the difference in the …
crucial for adequate dose personalization. Objective To quantify the difference in the …
Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology
These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …
original version published in 2011. They address the scope and targets of pharmacological …
Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical …
Background The antipsychotic, clozapine, is the only licensed drug against the treatment-
resistant symptoms that affect 20–30% of people with schizophrenia. Clozapine is markedly …
resistant symptoms that affect 20–30% of people with schizophrenia. Clozapine is markedly …
Antipsychotic treatment failure: a systematic review on risk factors and interventions for treatment adherence in psychosis
Objective: Antipsychotic medication non-adherence has detrimental effects on patients'
clinical outcome. It is unclear which risk factors affect adherence most and which …
clinical outcome. It is unclear which risk factors affect adherence most and which …
Clinical risk factors for the development of tardive dyskinesia
Background Tardive dyskinesia (TD) is a severe condition that can affect almost 1 out of 4
patients on current or previous antipsychotic treatment, including both first-generation …
patients on current or previous antipsychotic treatment, including both first-generation …
Dopamine and glutamate in antipsychotic-responsive compared with antipsychotic-nonresponsive psychosis: a multicenter positron emission tomography and …
The variability in the response to antipsychotic medication in schizophrenia may reflect
between-patient differences in neurobiology. Recent cross-sectional neuroimaging studies …
between-patient differences in neurobiology. Recent cross-sectional neuroimaging studies …
[HTML][HTML] Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre …
Background Evidence for the effectiveness of treatments in early-onset psychosis is sparse.
Current guidance for the treatment of early-onset psychosis is mostly extrapolated from trials …
Current guidance for the treatment of early-onset psychosis is mostly extrapolated from trials …